Department of Hematology, University of Kocaeli, Medical Faculty, Kocaeli, Turkey.
Med Oncol. 2011 Sep;28(3):846-51. doi: 10.1007/s12032-010-9533-0. Epub 2010 Apr 27.
The significance of vascular endothelial growth factor (VEGF) and heat shock protein-90 (HSP90) has received only limited attention especially in acute lymphoblastic leukemia (ALL). In this study, we assessed expressions of HSP90 and VEGF in bone marrow samples of patients with ALL and effect of these expression quantities on the mean overall survival.
Using immunohistochemical methods, we assessed expression of HSP90 and VEGF in 22 cases of ALL.
Expression of HSP90 was detected in 19/22 (86.4%) and 3/22 (13.6%) of patients with ALL, for strongly positive and moderate-weakly positive, respectively. Negative HSP90 expression was not detected in patients with ALL. Expression of HSP90 in patients with ALL and in control group were statistically significant (P<0.001), however, did not reflect the mean overall survival (P=0.910). Mean OS was evaluated 992±181 and 724.8±88.2 days for moderate-weak and high HSP90 expression, respectively. VEGF expressions were not significantly different between ALL and control groups (P<0.087). We did not find any relationship between HSP90 and VEGF expressions in bone marrow specimens of patients with ALL.
This study demonstrated that HSP90 expression grades in patients with ALL were significantly higher than that in controls and presence of strong HSP90 expression was associated with worse overall survival. VEGF expression in patients with ALL was not different from that in control samples. Determination HSP90 with immunohistochemical method in bone marrow can provide information about prognosis.
血管内皮生长因子 (VEGF) 和热休克蛋白 90 (HSP90) 的意义尤其在急性淋巴细胞白血病 (ALL) 中受到的关注有限。在这项研究中,我们评估了 HSP90 和 VEGF 在 ALL 患者骨髓样本中的表达,并研究了这些表达量对总生存率的影响。
我们使用免疫组织化学方法评估了 22 例 ALL 患者中 HSP90 和 VEGF 的表达。
在 22 例 ALL 患者中,有 19/22(86.4%)和 3/22(13.6%)患者 HSP90 表达为强阳性和中-弱阳性,未检测到 ALL 患者 HSP90 阴性表达。ALL 患者与对照组 HSP90 表达有统计学意义(P<0.001),但与平均总生存率无关(P=0.910)。中-弱 HSP90 表达组的平均 OS 为 992±181 天,高 HSP90 表达组为 724.8±88.2 天。ALL 患者与对照组 VEGF 表达无显著差异(P<0.087)。我们未发现 ALL 患者骨髓标本中 HSP90 与 VEGF 表达之间存在任何关系。
本研究表明,ALL 患者 HSP90 表达水平明显高于对照组,且强 HSP90 表达与总生存率较差相关。ALL 患者的 VEGF 表达与对照组样本无差异。骨髓免疫组织化学法测定 HSP90 可提供预后信息。